Joseph Leach, MD, medical oncologist at Minnesota Oncology, discusses the use of brigatinib (Alunbrig) in ALK-positive non–small cell lung cancer (NSCLC).
Joseph Leach, MD
Advertisement
Articles by Joseph Leach, MD
Advertisement
Latest Updated Articles
Dr. Leach on Brigatinib in ALK-Positive NSCLCPublished: September 21st 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Priority Review to Frontline Dato-DXd for Metastatic TNBC Ineligible for Immunotherapy
2
FDA Grants Fast Track Designation to Pelareorep Plus Bevacizumab/FOLFIRI in Second-Line KRAS-Mutant mCRC
3
On World Cancer Day, Northwell Highlights a Blueprint for Consistent, System-Wide Cancer Care
4
Leveraging AI for Optimal Clinical Trial Design in Oncology
5